Summary Transforming growth factor alpha (TGFa) and Transforming growth factor beta-I (TGF-P,) 
longer probability of survival at 80 months although the overall relapse free survival was not increased. EGFR mRNA expression was measured in 106 patients and was inversely correlated with ER status (P = 0.018). EGFR levels did not predict for early relapse or survival. TGFa mRNA levels were measured in 104 patients, no correlation was seen tumour size, node status, Er status, or clinical outcome.
The growth of breast cancer cells is regulated by numerous peptide growth factors including transforming growth factor alpha (TGF-alpha) (Salomon et al., 1984) and transforming growth factor beta-I (TGF-PI) (Knabbe et al., 1987) . As breast cancer cells express both the receptor and the ligand for numerous growth factors it has been suggested that an autocrine loop might be an important mechanism of growth regulation for breast cancer in vivo (Sporn & Todaro, 1980) . TGF-alpha is a 50 amino acid peptide which binds to the Epidermal growth factor receptor (EGFR) and is mitogenic for breast cancer cell lines in vitro. TGF-alpha has a more profound and prolonged action on EGFR than Epidermal growth factor itself. It has been reported that TGF alpha synthesis is regulated both in vitro (Bates et al., 1988) and in vivo (Lui et al., 1987) by oestrogens suggesting a possible role in mediating the effect of endocrine therapy. The importance of a possible autocrine loop in breast cancer involving TGFalpha is suggested by several studies that have shown a correlation between high levels of EGFR in tumour biopsies and early relapse and survival (Toi et al., 1990 ; Lewis et al., 1990; Grimaux et al., 1989; Rios et al., 1988; Sainsbury et al., 1987) .
The TGF-betas are a family of multifunctional growth factors. The best characterised of these peptides is TGF-P, which is a 25 kDa homodimer which is synthesised by a wide variety of both normal and malignant cells (Derynck et al., 1985) . TGF-P, has multiple actions including both stimulatory and inhibitory effects on cell growth although its predominant effect on epithelial cells is inhibitory. It has effects on cellular differentiation, is a chemotactic agent and has numerous effects on extracellular matrix control (Sporn & Roberts, 1989) . It has been reported that members of the TGF beta family are regulated in vitro by oestrogen (Arrick et al., 1990) and that the anti-oestrogen Tamoxifen increases secretion of locally active TGF beta from breast cancer cells (Knabbe et al., 1987) and stromal fibroblasts (Colletta et al., 1990 (Ullrich et al., 1984) , TGF alpha (Derynck et al., 1984) , TGF-P1 (Derynck et al., 1985) and beta-Actin (Ponte et al., 1984) were excised from plasmids and labelled with alpha-32P-dCTP (Amersham, UK) by the random primer method (Feinberg & Vogelstein, 1983) .
Total cellular RNA was extracted from 0.5-1 gm of frozen tissue as previously described (Chirgwin et al., 1979) . In 10 cases polyadenylated (Poly(A)+) mRNA was obtained by one passage through oligo (dT) cellulose (Aviv & Leder, 1972) .
To assess the integrity of the RNA extracted all samples were fractionated on Loening phosphategels (Loening & Ingle, 1967) prior to dot-blot analysis. Samples showing evidence of degradation by loss of clear ribosomal bands were discarded. This also served as a check of the concentration of RNA loaded as equal amounts of RNA loaded would fluoresce equally under UV illumination.
For dot blot analysis serial dilutions of denatured RNA were applied to Hybond membranes (Amersham, UK) using a Bio-Dot apparatus (Bio-Rad, UK) as previously described (Barrett-Lee et al., 1987) . Serial dilutions of the plasmid being studied and of non-homologous RNA were applied to the membrane to quantify the signal and assess the extent of non-specific hybridisation. For each cDNA probe several tumour samples were analysed by Northern blotting to assess transcript size. For northern analysis (Thomas, 1980) 2.5 ,.g poly (A)' or 20 jig total mRNA per sample were resolved in a formaldehyde/agarose gel and blotted onto Hybond-N membrane. Denatured RNA markers were also run to enable sizing of hybridising bands.
Filters were prehybridised at 42°C for 4 h in 50% deionised formamide, 0.1% sodium dodecyl sulphate (SDS), 5 x Denhart's solution (1 x Denhart's = 0.02% each of polyvinylpyrrolidine, bovine serum albumin and Ficoll). Five mm EDTA, 0.75 M NaCl and 50 mM NaH2PO4 pH 8.3
and denatured salmon sperm DNA (250 jg ml-').
Filters were hybridised overnight under the same conditions as for prehybridisation with the addition of 1-5 x 106 c.p.m. ml-' of denatured cDNA probe.
After hybridisation filters were washed with three changes of 2 x SSC (20 x SSC = 3 M NaCl, 0.3 M trisodium citrate, pH7), 0.1% SDS at room temperature and two changes of 0.1 x SSC, 0.1% SDS at 65°C. Autoradiography was carried out using Hyperfilm MP (Amersham, UK) with intensifying screens at -70°C for 4-14 days. To assess the degree of loading of mRNA onto the membranes the membranes were stripped by immersing in 0.1% SDS at 100°C for two hours. Representative filters were then hybridised to the cDNA probe to beta-Actin as described above to ensure that equal loading of RNA had occurred.
Quantification of mRNA was carried out by comparison with serial dilutions of the appropriate plasmid with a scale of + + + + + to + as previously described. (Barrett-Lee et al., 1987) . For TGF-P, this was by densitometry while for EGFR and TGF-a the low levels of RNA expression was assessed visually.
Oestrogen receptor determination Measurement of ER was by a modification of the dextran coated charcoal assay (McGuire & De La Garza, 1973) or alternatively for small samples ER was estimated by an immunocytochemical assay as previously described (McClelland et al., 1986) . Using the biochemical assay, carcinomas with > 10 fmol mg-' were considered ER positive while with the immunocytochemical assay, tumours with >25% staining were considered ER positive. There was no correlation of TGF-P1 with T stage. We also i u i examined whether there was any correlation of TGF-P, expression with TGF-o or EGFR but no correlation was seen (Data not shown).
The influence of TGF-P13 mRNA levels on relapse free survival and survival was examined by life table analysis in 167 patients (Figure 1 a and There was no evidence that TGF-o mRNA levels had any influence on either relapse free or overall survival (Figure 2a and b). a EGFR One hundred and six tumours were examined for EGFR mRNA expression by dot-blot analysis. 55 (51%) had detectable levels which were scored as + or + +. Transcripts of 10.0, 6.4 and 4.8 kb were detected by Northern analysis. In 87 tumours the ER status was known and there was a significant inverse correlation of EGFR positivity with ER status. (Chi2 = 6.69 P = 0.018). No correlation was seen with pathological nodal status in 86 patients where this was known. From life table analysis there was no evidence from this study in 107 patients with clinical follow up that EGFR mRNA levels predicted either early relapse or death (Figure  3a and b) . We found no evidence that co-expression of TGF-a and EGFR was associated with a poor prognosis (data not shown).
Discussion
This study has addressed the question as to whether the expression (at the mRNA level) of TGF-p1, TGF-a or EGFR can have clinical significance. Both epidermal growth factor and TGF-a cause proliferation of breast carcinoma cell in vitro and several reports have indicated that levels of EGFR are related to prognosis in breast cancer (Toi et al., 1990 ; Lewis et al., 1990; Grimaux et al., 1989; Rios et al., 1988; Sainsbury et al., 1987) . Other studies have not confirmed this (Foekens et al., 1989; Hawkins et al., 1991) and the exact importance of EGFR levels in breast cancer as a prognostic determinant remains controversial. Our study found an inverse correlation of EGFR with ER status which confirms the reports from other studies (Toi et al., 1990; Lewis et al., 1990; Bolufer et al., 1990; Rios et al., 1988; Foekens et al., 1989) . The correlation with other tumour parameters noted by other workers was not found in this study. A correlation with nodal status (Bolufer et al., 1990) , lymphatic invasion (Toi et al., 1990) , and tumour size (Sainsbury et al., 1988) , 1990) . The same argument applies to the relationship between mRNA expression and protein expression of TGF-P, and TGF-a but these are not clearly characterised.
As the major ligand for EGFR is TGF-a in breast cancer it is of interest to speculate that tumour levels of TGF-a might effect the natural history of the disease. Recently it has been reported that high levels of TGF-x as measured immunocytochemically correlates with a poor prognosis in adenocarcinoma of the lung (Tateishi et al., 1991) . Previous investigators have examined TGF-a expression in small series of patients with breast cancer and have found no evidence of a correlation with ER status, node status or prognosis (Ciardiello et al., 1989; Bates et al., 1988) . This is confirmed in our series which is the largest series to date examining this question.
Low levels of TGF-,B, mRNA were found to be associated with node positivity and a shorter relapse free survival. TGF-PI is a member of a family of peptides which are highly conserved in nature and are multifunctional. TGF-PI is generally inhibitory to epithelial cells in vitro and has several effects on the regulation of extracellular matrix components (Sporn & Roberts, 1989) . TGF-,B increases the transcription of the genes for collagen and fibronectin while it decreases the secretion of members of the metalloproteinase family. TGF-,B also increases the production of protease inhibitors including plasminogen activator inhibitor and the tissue inhibitors of metalloproteinase TIMPI and TIMP2. There is accumulating evidence that the metastatic behaviour of a tumour is strongly determined by its ability to breakdown basement membrane possibly by the increased production of collagenase (Liotta et al., 1991) . It is likely that natural tissue proteinase inhibitors would potentially inhibit this invasive process. High levels of TGF-1, may protect against invasion by locally regulating basement membrane components and protease action. TGF-P1 is hormonally regulated in vitro and several investigators have demonstrated that the antioestrogen Tamoxifen increases the secretion of TGF-P3 (Knabbe et al., 1987; Colletta et al., 1990) suggesting that this might be an important mediator in the mechanism of endocrine therapy, possibly through the above mechanism.
The potential interplay between TGF-P3 and other members of the TGF-P family in human breast cancer together with the many known actions of this family of growth factors argues against a simplistic explanation of the role of TGF-P1 in this disease. However these data suggest that further studies into the possible role of TGF-,B, as a prognostic indicator or as a potential target for novel therapy in breast cancer are warranted.
